Wellness
Interview: The US company appealing Europe’s rejection of daily Alzheimer’s pill
Despite having its application for a new, daily Alzheimer’s pill rejected by Europe’s regulators the CEO of US drug company Anavex Life Sciences is appealing this decision.
A Phase IIb/III trial found over one-third of patients with mild Alzheimer’s – those with a Mini-Mental State Examination (MMSE) score of between 20 and 28 – experienced a slowing of their ‘cognitive decline’.
And, for the majority of the population – those with the common sigma-1 gene – the results were even more dramatic, slowing decline by 49.8%.
Despite this success, in December last year, the European medical authorities rejected an application for the drug – known as Blarcamesine – saying the study ‘failed to demonstrate effectiveness and safety’.
Within days Anavex initiated a challenge to the decision. It has called for a re-examination of the evidence and this is now being undertaken by the European Medicines Agency (EMA).
Speaking to Agetech World Dr Christopher Missling, president and CEO of Anavex, said: “The trial data showed that patients actually improved their quality of life.
“The Alzheimer’s patients had a higher quality of life at the end of the trial than at baseline.”
What Is Blarcamesine?
Unlike other treatments targeting Alzheimer antagonists, such as amyloid-beta or tau pathology, Blarcamesine acts upstream by activating sigma-1 receptors.
This permits the restoration of autophagy – the intracellular recycling and cleaning system which is impaired in pathologies such as Alzheimer’s.
Alzheimer treatments such as Leqembi – which has been approved in over 50 counties and targets amyloid-beta plaques in the brain to slow Alzheimer progression – require regular hospital infusions and carry the risk of brain swelling and bleeding.
Blarcamesine is a pill, taken orally, with no evidence of damaging side effects, such as brain swelling or micro-bleeding, eliminating the need for frequent MRI monitoring required for other drugs.
Dr Missling said: “None of this would be required with Blarcamesine, which is a once-daily, simple oral pill you can ship anywhere.
“The efficacy is also extremely favourable; we see a double or more benefit of cognition and function compared to those injectable antibodies. So, it potentially offers a strong advantage not only in safety and convenience but also in efficacy.”
Why was it rejected by the EU?
A statement from the EMA outlined its position: “In December 2025, EMA’s human medicines committee, the Committee for Medicinal Products for Human Use (CHMP), concluded that the main study failed to demonstrate effectiveness and safety of Blarcamesine Anavex in patients with early Alzheimer’s disease who do not have a mutation in the sigma-1 gene.”
It went on to say that Anavex has requested a ‘re-examination of EMA’s opinion issued on December 11, 2025…(and) the agency will re-examine its opinion and issue a final recommendation’.
Concerns raised by the CHMP focused on trial methodology, possible side effects in the nervous system, and impurities that could potentially cause cancer.
Dr Missling highlighted how a lengthening of the titration process had addressed the mild-dizziness issue and the impurity concerns, which centred on an acceptable threshold for nitrosamines, has also been negated.
And, he highlighted how the amyloid-beta plaque-targeting drugs Leqembi and Kisunla – which have been fully approved in the US – were eventually approved in Europe after a similar re-examination process .
USA application
Anavex has started a dialogue with the US Food and Drug Administration which has requested access to all of its trial data and if approved in the USA it will open-up the potential for global market authorisation.
The potential size of the market for Blarcamesine is huge, with the number of adults suffering from Alzheimer’s disease expected to grow from around 60 million to 150 million by 2050, as the global population ages.
Dr Missling on how Blarcamesine works
“Blarcamesine activates the Sigma-1 receptor in vivo, which has been confirmed in several peer-reviewed publications and established with a PET study demonstrating dose-dependent activation in the brain.
“The sigma-1 is an integral membrane protein involved in restoring cellular homeostasis. It activates an upstream compensatory process – autophagy – through sigma-1 activation.
“Autophagy gets impaired over time during aging and especially during pathologies like Alzheimer’s and Parkinson’s. This is a very important process, which is nothing else but the recycling of neurons who cannot get rid of their ‘trash’, if you like; they have to recycle it. If this mechanism is impaired, those cells eventually die.
“It stands at the top of many cascades of this complex pathology, for example, on top of A-beta aggregation or Tau aggregation.
“That’s why it’s intriguing to try to approach this from a more comprehensive upstream viewpoint.
Blarcamesine is a small molecule you can take once a day. It restores homeostasis, reactivates impaired autophagy, and lets the body function as it does in a healthy fashion.”
Gut-friendly foods such as kimchi and kombucha may carry hidden risks for heart health when eaten in excess, the British Heart Foundation (BHF) has warned.
The charity said foods marketed as prebiotic, probiotic or otherwise good for the gut can support the microbiome, but some may also be high in salt or sugar, which can raise the risk of cardiovascular disease.
Products highlighted by the British Heart Foundation included kimchi, kombucha, fruit yoghurts, smoothies and sauerkraut. It said there is no harm in including them as part of a healthy diet, but advised people to check labels for added salt and sugar and eat them in moderation.
Tracy Parker, the charity’s nutrition lead, said: “We encourage everyone to choose foods that can keep their gut microbiome healthy. The benefits are clear, and we are continuing to improve our understanding of how a gut-friendly diet may help our hearts.
“A lot of these products can contain high levels of salt or sugar though, so it is important to be aware of the potential drawbacks.
“By ensuring you check package labels for added salt and sugars, and eat each in moderation, you can make sure the risks do not outweigh the benefits for your heart health.”
Fermented foods such as kimchi and sauerkraut are rich in probiotics, the healthy bacteria produced during fermentation that can help support a diverse and healthy gut microbiome.
However, both are traditionally made using a lot of salt, which can raise blood pressure if eaten frequently or in large quantities. High blood pressure is known to increase the risk of heart attack and stroke.
Kombucha, a fermented tea, also contains probiotics and can be a healthier alternative to fizzy drinks, but many commercial and shop-bought versions contain added sugar.
Eating too much sugar can lead to weight gain, which can increase the risk of heart attack, stroke and other cardiovascular disease.
Fruit yoghurts can contain probiotic live bacteria cultures, but may also be high in sugar and have fewer live cultures than plain versions.
The charity said plain yoghurt with live and active cultures on the label can be a lower-sugar option, with whole fruit added at home for sweetness.
Smoothies made with whole fruits provide prebiotic fibre, which feeds beneficial gut bacteria and supports digestive health.
They can also provide vitamins and antioxidants, especially when made with a variety of plant-based ingredients.
But blending breaks down the structure of fruit, releasing free sugars that behave like added sugars in the body and can cause faster rises in blood sugar levels.
Regularly consuming too much sugar can lead to weight gain, which can increase the risk of developing type 2 diabetes, heart disease and kidney disease.
The charity said only one 150ml serving of any smoothie counts towards five-a-day, and suggested adding nuts or seeds for extra protein and fibre to help keep blood sugar levels more stable.
The BHF also noted that some shop-bought sauerkraut is pasteurised, which removes most of the live bacteria.
It advised checking the label, eating small portions and choosing unpasteurised products for those seeking the probiotic benefits.
The charity said beneficial gut bacteria produce short-chain fatty acids during digestion, which are linked to reduced inflammation, better metabolism and better heart and circulatory health.
These good bacteria also help digest polyphenols, natural plant chemicals thought to have antioxidant properties and which may help lower blood pressure.
By contrast, harmful gut bacteria, which thrive on diets high in fat and red meat, produce chemicals that can cause problems in the heart and blood vessels by increasing inflammation and altering how cholesterol is processed in the body.
Beneficial bacteria thrive on varied diets high in prebiotics, non-digestible fibres found in foods such as wholegrains, oats, beans, lentils, bananas and onions.
People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.
Gut-friendly foods may damage heart, charity warns
Diabetes patients face increased risk of undiagnosed heart failure
UK government announces £6.3m fund to boost men’s health
Brain health collaboratory launches in Gulf South
